OPRX Stock Overview
A digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
OptimizeRx Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.60 |
| 52 Week High | US$16.65 |
| 52 Week Low | US$6.92 |
| Beta | 1.26 |
| 11 Month Change | -19.63% |
| 3 Month Change | -33.54% |
| 1 Year Change | 15.28% |
| 33 Year Change | -87.16% |
| 5 Year Change | -47.59% |
| Change since IPO | -96.63% |
Recent News & Updates
Recent updates
OptimizeRx (NASDAQ:OPRX) Is Carrying A Fair Bit Of Debt
Jul 30
OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors
Jan 09Analyst Forecasts Just Became More Bearish On OptimizeRx Corporation (NASDAQ:OPRX)
Aug 24OptimizeRx Corporation (NASDAQ:OPRX) Shares May Have Slumped 38% But Getting In Cheap Is Still Unlikely
Aug 16Is Now An Opportune Moment To Examine OptimizeRx Corporation (NASDAQ:OPRX)?
May 31OptimizeRx: A Top Candidate For My Speculative 'Bio Boom' Portfolio
Oct 12Is Now The Time To Look At Buying OptimizeRx Corporation (NASDAQ:OPRX)?
Sep 23OptimizeRx extends reach with Cooler Screens Partnership
Jul 26OptimizeRx: A Small-Cap Digital Health Technology Gem With Near-Term Inflection In Profitability
Jun 27The Strong Earnings Posted By OptimizeRx (NASDAQ:OPRX) Are A Good Indication Of The Strength Of The Business
Nov 16Why We Think OptimizeRx Corporation's (NASDAQ:OPRX) CEO Compensation Is Not Excessive At All
Aug 13A Look At The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)
Jul 15Here's Why We're Not At All Concerned With OptimizeRx's (NASDAQ:OPRX) Cash Burn Situation
Jun 24Investors Will Want OptimizeRx's (NASDAQ:OPRX) Growth In ROCE To Persist
May 10Estimating The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)
Mar 29Don't Ignore The Fact That This Insider Just Sold Some Shares In OptimizeRx Corporation (NASDAQ:OPRX)
Feb 21Shareholder Returns
| OPRX | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 3.1% | 4.9% | 1.6% |
| 1Y | 15.3% | -1.7% | 26.3% |
Return vs Industry: OPRX exceeded the US Healthcare Services industry which returned -1.7% over the past year.
Return vs Market: OPRX underperformed the US Market which returned 26.3% over the past year.
Price Volatility
| OPRX volatility | |
|---|---|
| OPRX Average Weekly Movement | 6.1% |
| Healthcare Services Industry Average Movement | 9.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: OPRX's share price has been volatile over the past 3 months.
Volatility Over Time: OPRX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 136 | Will Febbo | www.optimizerx.com |
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.
OptimizeRx Corporation Fundamentals Summary
| OPRX fundamental statistics | |
|---|---|
| Market cap | US$157.57m |
| Earnings (TTM) | -US$17.91m |
| Revenue (TTM) | US$83.20m |
1.9x
P/S Ratio-8.8x
P/E RatioIs OPRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OPRX income statement (TTM) | |
|---|---|
| Revenue | US$83.20m |
| Cost of Revenue | US$31.65m |
| Gross Profit | US$51.55m |
| Other Expenses | US$69.46m |
| Earnings | -US$17.91m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.98 |
| Gross Margin | 61.96% |
| Net Profit Margin | -21.53% |
| Debt/Equity Ratio | 29.4% |
How did OPRX perform over the long term?
See historical performance and comparison